Osama O. Zaidat

Osama O. Zaidat

Auto-generated profile, based on publicly available information

Osama O. Zaidat

Department of Neurology, Medical College of Wisconsin/Froedtert Hospital, Milwaukee2Department of Neurosurgery, Medical College of Wisconsin/Froedtert Hospital, Milwaukee3Department of Radiology, Medical College of Wisconsin/Froedtert Hospital, Milwaukee

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Stroke
Verified
Journal Article
Closed access
PDF file
OZOsama O. Zaidat
Osama O. Zaidat
AYAlbert J. Yoo
Albert J. Yoo
PKPooja Khatri
Pooja Khatri
TTThomas A. Tomsick
Thomas A. Tomsick
RKRüdiger von Kummer
Rüdiger von Kummer
DLDavid S. Liebeskind
David S. Liebeskind

24 March 2015 in JAMA
Verified
Journal Article
Open access
PDF file
OZOsama O. Zaidat
Osama O. Zaidat
BFBrian-Fred Fitzsimmons
Brian-Fred Fitzsimmons
BWBritton Keith Woodward
Britton Keith Woodward
ZWZhigang Wang
Zhigang Wang
MKMonika Killer-Oberpfalzer
Monika Killer-Oberpfalzer
DGDaryl R. Gress
Daryl R. Gress
Intracranial arterial stenosis is a common stroke etiology worldwide.1-6 The recurrent stroke risk with severe symptomatic intracranial stenosis (≥70%) may be as high as 23% at 1 year, despite medical therapy.7,8 Endovascular options are limited to balloon angioplasty only, self-expanding stent, balloon-expanding stent, or a combination of these therapies. The SAMMPRIS (Stenting and Aggressive Medical Therapy for Preventing Recurrent Stroke in Intracranial Stenosis) trial showed that aggressive medical therapy alone was superior to percutaneous transluminal balloon angioplasty followed by stenting using the Wingspan self-expanding stent (Stryker) with an absolute difference of 8.9% at 30 days and 9.0% at 3 years in the primary outcome.9-11 The 30-day event rates with medical therapy were nearly one-half of the reported event rates in the WASID (Warfarin-Aspirin Symptomatic Intracranial Disease) trial and the balloon angioplasty with stenting results were nearly double the rates that were reported in prior stenting registries.7,8,12-14

22 April 2008 in Neurology
Verified
Journal Article
Closed access
PDF file
OZO. O. Zaidat
O. O. Zaidat
RKR. Klucznik
R. Klucznik
MAM. J. Alexander
M. J. Alexander
JCJ. Chaloupka
J. Chaloupka
HLH. Lutsep
H. Lutsep
MCM. Chimowitz
M. Chimowitz
Background: The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial showed that patients with symptomatic 70% to 99% intracranial arterial stenosis are at particularly high risk of ipsilateral stroke on medical therapy: 18% at 1 year (95% CI = 3% to 24%). The Wingspan intracranial stent is another therapeutic option but there are limited data on the technical success of stenting and outcome of patients with 70% to 99% stenosis treated with a Wingspan stent. Methods: Sixteen medical centers enrolled consecutive patients treated with a Wingspan stent in this registry between November 2005 and October 2006. Data on stenting indication, severity of stenosis, technical success (stent placement across the target lesion with <50% residual stenosis), follow-up angiography, and outcome were collected. Results: A total of 129 patients with symptomatic 70% to 99% intracranial stenosis were enrolled. The technical success rate was 96.7%. The mean pre and post-stent stenoses were 82% and 20%. The frequency of any stroke, intracerebral hemorrhage, or death within 30 days or ipsilateral stroke beyond 30 days was 14.0% at 6 months (95% CI = 8.7% to 22.1%). The frequency of ≥50% restenosis on follow-up angiography was 13/52 (25%). Conclusion: The use of a Wingspan stent in patients with severe intracranial stenosis is relatively safe with high rate of technical success with moderately high rate of restenosis. Comparison of the event rates in high-risk patients in Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) vs this registry do not rule out either that stenting could be associated with a substantial relative risk reduction (e.g., 50%) or has no advantage compared with medical therapy. A randomized trial comparing stenting with medical therapy is needed. GLOSSARY: FDA = Food and Drug Administration; HDE = Humanitarian Device Exemption; ICH = intracerebral hemorrhage; WASID = Warfarin-Aspirin Symptomatic Intracranial Disease.

1 December 2014 in Stroke
Verified
Journal Article
Closed access
ACAlicia C. Castonguay
Alicia C. Castonguay
OZOsama O. Zaidat
Osama O. Zaidat
RNRoberta Novakovic
Roberta Novakovic
TNThanh N. Nguyen
Thanh N. Nguyen
MTM. Asif Taqi
M. Asif Taqi
RNRaul G. Nogueira
Raul G. Nogueira
Background and Purpose—: The Solitaire With the Intention for Thrombectomy (SWIFT) and thrombectomy revascularization of large vessel occlusions in acute ischemic stroke (TREVO 2) trial results demonstrated improved recanalization rates with mechanical thrombectomy; however, outcomes in the elderly population remain poorly understood. Here, we report the effect of age on clinical and angiographic outcome within the North American Solitaire-FR Stent-Retriever Acute Stroke (NASA) Registry. Methods—: The NASA Registry recruited sites to submit data on consecutive patients treated with Solitaire-FR. Influence of age on clinical and angiographic outcomes was assessed by dichotomizing the cohort into ≤80 and >80 years of age. Results—: Three hundred fifty-four patients underwent treatment in 24 centers; 276 patients were ≤80 years and 78 were >80 years of age. Mean age in the ≤80 and >80 cohorts was 62.2±13.2 and 85.2±3.8 years, respectively. Of patients >80 years, 27.3% had a 90-day modified Rankin Score ≤2 versus 45.4% ≤80 years ( P =0.02). Mortality was 43.9% and 27.3% in the >80 and ≤80 years cohorts, respectively ( P =0.01). There was no significant difference in time to revascularization, revascularization success, or symptomatic intracranial hemorrhage between the groups. Multivariate analysis showed age >80 years as an independent predictor of poor clinical outcome and mortality. Within the >80 cohort, National Institutes of Health Stroke Scale (NIHSS), revascularization rate, rescue therapy use, and symptomatic intracranial hemorrhage were independent predictors of mortality. Conclusion—: Greater than 80 years of age is predictive of poor clinical outcome and increased mortality compared with younger patients in the NASA registry. However, intravenous tissue-type plasminogen activator use, lower NIHSS, and shorter revascularization time are associated with better outcomes. Further studies are needed to understand the endovascular therapy role in this cohort compared with medical therapy.

1 January 2011 in Frontiers in Neurology
Verified
Journal Article
Open access
MLMarc A. Lazzaro
Marc A. Lazzaro
ABAamir Badruddin
Aamir Badruddin
OZOsama O. Zaidat
Osama O. Zaidat
ZDZiad Darkhabani
Ziad Darkhabani
DPDhruvil J. Pandya
Dhruvil J. Pandya
JLJohn R. Lynch
John R. Lynch
Endovascular tumor embolization as adjunctive therapy for head and neck cancers is evolving and has become an important part of the tools available for their treatment. Careful study of tumor vascular anatomy and adhering to general principles of intra-arterial therapy can prove this approach to be effective and safe. Various embolic materials are available and can be suited for a given tumor and its vascular supply. This article aims to summarize current methods and agents used in endovascular head and neck tumor embolization and discuss important angiographic and treatment characteristics of selected common head and neck tumors.

25 September 2012 in Neurology
Verified
Journal Article
Closed access
PDF file
OZO.O. Zaidat
O.O. Zaidat
MLM.A. Lazzaro
M.A. Lazzaro
DLD.S. Liebeskind
D.S. Liebeskind
NJN. Janjua
N. Janjua
LWL. Wechsler
L. Wechsler
PKP. Khatri
P. Khatri
Background: Recanalization and angiographic reperfusion are key elements to successful endovascular and interventional acute ischemic stroke (AIS) therapy. Intravenous recombinant tissue plasminogen activator (rt-PA), the only established revascularization therapy approved by the US Food & Drug Administration for AIS, may be less effective for large artery occlusion. Thus, there is enthusiasm for endovascular revascularization therapies, which likely provide higher recanalization rates, and trials are ongoing to determine clinical efficacy and compare various methods. It is anticipated that clinical efficacy will be well correlated with revascularization of viable tissue in a timely manner. Method: Reporting, interpretation, and comparison of the various revascularization grading methods require agreement on measurement criteria, reproducibility, ease of use, and correlation with clinical outcome. These parameters were reviewed by performing a Medline literature search from 1965 to 2011. This review critically evaluates current revascularization grading systems. Results and Conclusion: The most commonly used revascularization grading methods in AIS interventional therapy trials are the thrombolysis in cerebral ischemia (TICI, pronounced “tissy”) and thrombolysis in myocardial ischemia (TIMI) scores. Until further technical and imaging advances can incorporate real-time reliable perfusion studies in the angio-suite to delineate regional perfusion more accurately, the TICI grading system is the best defined and most widely used scheme. Other grading systems may be used for research and correlation purposes. A new scale that combines primary site occlusion, lesion location, and perfusion should be explored in the future.